HYDERABAD, Jan 24 : Alleging that Congress was never democratic during its long rule in the country, Union Minister G Kishan Reddy on Friday stated that the BJP does not need Rahul Gandhi’s ...

In an interview with India Today TV, Reddy also took a swipe at BRS working president KT Rama Rao by calling him an IT employee with a "worker mindset". Speaking to India Today News Director Rahul ...

As Leader of the Opposition (LoP) in the Lok Sabha Rahul Gandhi launched a white T-shirt movement – based on the trademark T-shirt he has sported since his Bharat Jodo Yatra in 2022 even during ...

Reddy Customs, an automotive customization company, introduced four vehicle modifications at the Bharat Mobility Global Expo 2025 in New Delhi. The showcase includes a Mercedes G-Wagon, a Mercedes ...

Subscribe to The Economic Times Prime and read the ET ePaper online.

Indian pharmaceutical major, Dr Reddy’s Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025. According ...

A First Information Report (FIR) was registered against Congress leader Rahul Gandhi in Guwahati for allegedly provoking rebellion against the Indian state. Monjit Chetia, a Guwahati-based ...

Middle class, women, poor dominate Modi's pre-Budget speech. Relief ahead? Economic Survey offers hope to 'aam aadmi' on inflation pains, subject to terms and conditions India Inc earns fat profits ...

Rahul Gandhi has no right to come to Telangana”, said G Kishan Reddy. New income tax slabs for FY 2025-26: 30% tax now starts at Rs 24 lakh, income up to Rs 20 lakh to be taxed at 20% in Budget ...

"Why were more voters added in 5 months than in 5 years?" Rahul Gandhi alleges voting irregularities in Maharashtra ...

The Stree 2 actress has once again set social media abuzz with rumours about her love life with screenwriter, Rahul Mody. This time, her cutesy Instagram story has fans speculating whether the couple ...

BofA has chosen Dr. Reddy's Laboratories Ltd. as its top pick in the Indian pharma space, as its sees earnings visibility in the near term. Two years of outperformance-boosted valuation and gross ...